2019 ASH Annual Meeting Perspectives
December 23, 2019
Share:
In order to tackle our clients’ most difficult challenges and build leaders in life sciences, Clarion is committed to staying abreast of the latest developments for the treatment of hematologic diseases. As such, our team attended the ASH (American Society of Hematology) 2019 Annual Meeting and we are pleased to share the following perspectives on key advances across hematologic oncology and genetic blood disorders:
Key Takeaways
- Multiple myeloma is undergoing transformation on at least two fronts: CAR-T and bispecific therapies targeting BCMA are revolutionizing late-line treatment, while daratumumab-based combinations drive deeper and longer responses in the frontline setting
- AML/MDS is seeing exciting innovation: venetoclax is reshaping standards of care, agents targeting leukemic stem cells show compelling signals, and diverse other therapies continue to emerge across treatment settings
- For NHL and ALL, CD19 CART produces new data but faces new challengers from new players, bispecifics, ADCs, new mechanisms, and eventually off-the-shelf cell therapies
- CLL’s dominant therapy, ibrutinib, faces intense competition from other BTK inhibitors and other mechanisms
- Genetic blood disorders are at the beginning of a new era of treatment led by innovative targeted therapies for sickle cell disease and beta-thalassemia, and by gene therapies for many other conditions